期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利妥昔单抗诱导性肺损伤 被引量：3

下载PDF
导出
摘要 利妥昔单抗（Rituxmab，RTX）是一种人／鼠嵌合型免疫球蛋白G1-κ型单克隆抗体，与表达在B细胞和部分T细胞表面CD20分子特异性结合，通过激活补体和NK细胞，诱导细胞凋亡。
作者 胡小龙 刘一 张波
机构地区 空军总医院呼吸科
出处 《临床肺科杂志》 2012年第8期1471-1473,共3页 Journal of Clinical Pulmonary Medicine
关键词 利妥昔单抗 肺损伤 诱导性 CD20分子 诱导细胞凋亡 单克隆抗体 免疫球蛋白 特异性结合
分类号 R595.3 [医药卫生—内科学]
  • 相关文献

参考文献18

  • 1Friedberg JW. Unique toxicities and resistance mechanisms associ- ated with monoclonal antibody therapy [ J ]. Hematology Am Soc He- matol Educ Program ,2005:329 - 334.
  • 2Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fiudarabine with eoneunrrent versus sequential treatment with rituxmab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9/12( CALGB 9712) [ J]. Blood 2003 ;101 ( 1 ) :6 - 14.
  • 3Sibilia J, Gottenberg JE, Mariette X. Rituxmab : a new therapeutic alternative in rheumatoid arthritis [ J ]. Joint Bone Spine 2008 ; 75 (5) :526 -532.
  • 4易慧,郭禹标,曾勉,谢灿茂.利妥昔单抗致间质性肺疾病1例[J].实用医学杂志,2009,25(10):1721-1722. 被引量：3
  • 5Liote H, Liote F. Rituxmab-induced lung disease:a systematic liter- ature review [ J ]. Eur Respir J, 2010,35 ( 3 ) :681 - 687.
  • 6Kimby E. Tolerability and safety of rituxmab [ J ]. Cancer Treat Rev,2005,31 (6) :456 -473.
  • 7Gonzalez V, Salgueiro E, Jimeno FJ, et al. Post-marketing safety of antineoplasic monoclonal antibodies; rituxmab and trastuzumab [ J ]. Pharmacoepidemiol Drug Saf,2008,17 (7) :714 - 21.
  • 8Liu X,Hong XN,Gu YJ,et al. Interstitial pneumonitis during ritux- mab-containing chemotherapy for non-Hodgkin lymphoma[ J ]. Leuk Lymphoma,2008,49 : 1778 - 1783.
  • 9Ennishi D,Terui Y,Yokoyama M,et al. Increased incidence of in- temtitial pneumonia by CHOP combined with rituxmab[ J ]. Int J He- matol,2008,87 (4) : 393 - 7.
  • 10Murali S, Manjunath R, Nalini K, et al. Rituxmab-induced subacute interstitial pneumonitis: A case report and review of literature [ J ]. Journal of Cancer Research and Therapeutics ,2010,6(3 ) :344 -6.

二级参考文献11

  • 1Bienvenu J,Chvetzoff R,Salles G,et al.Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment[J].Hematol J,2001,2(6):378-384.
  • 2Burton C,Kaczmarski R,Jan-Mohamed R.Interstitial pneumonitis related to rituximab therapy[J].New Engl J Med,2003,348 (26):2690-2691.
  • 3Byrd J C,Peterson B L,Morrison V A,et al.Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic,untreated patients with Bcell chronic lymphocytic leukemia:results from Cancer and Leukemia Group B 9712(CALGB 9712)[J].Blood,2003,101(1):6-14.
  • 4Swords R,Power D,Fay M,et al.Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)[J].Am J Hematol,2004,77(1):103-104.
  • 5Alexandreseu D T,Dutcher J P,O' Boyle K,et al.Fatal intra-alveolar hemorrhage after rituximab in a patient with nonHodgkin lymphoma[J].Leuk Lymphoma,2004,45 (11):2321-2325.
  • 6Hiraga J,Kondoh Y,Taniguchi H,et al.A case of interstitial pneumonia induced by rituximab therapy[J].Int J Hematol,2005,81 (2):169-170.
  • 7Leon R J,Gonsalvo A,Salas R,et al.Rituximab-induced pulmonary fibrosis[J].Mayo din Pro,2004,79(7):949-653.
  • 8Ghesquieves H.Severe interstitial pneumenitis following rituximab and bleomycin-containing chemotherapy[J].Ann Oncol,2005,16(8):1399.
  • 9BiehnS E,Kirk D,RiveraM P,et al.Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for nonHodgkin's lymphoma[J].Hematol Oncol,2006,24(4):234-237.
  • 10Wagner S A,Mehta A C,Laber D A.Rituximab-induced interstitial lung disease[J].Am J Hematol,2007,82(10):916-919.

共引文献2

同被引文献23

  • 1朱玉珍,冯勤富.放射疗法和化学疗法结合致肺组织损伤的研究进展[J].中国肿瘤,2005,14(8):534-537. 被引量：3
  • 2Kimby E. Tolerability and safety of rituximab[J]. Cancer Treat Rev, 2005, 31(6): 456-473.
  • 3Friedberg JW. Unique toxicities and resistance mechanisms as- sociated with monoclonal antibody therapy[J]. Hematology Am Soc Hematol Educ Program, 2005, 1(1): 329-334.
  • 4Sibilia J, Gottenberg JE, Mariette X. Rituximab: a new ther- apeutic alternative in rheumatoid arthritis [J]. Joint Bone Spine, 2008, 75(5): 526-532.
  • 5Gonz/dez V, Salgueiro E, Jimeno FJ, et al. Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab[J]. Pharmacoepidemiol Drug Saf, 2008, 17(7) : 714-721.
  • 6Smolen JS, Keystone EC, Emery P, et al. Consensus state- ment on the use of rituximab in patients with rheumatoid ar- thritis[J]. Ann Rheum Dis, 2007, 66(2) : 143-150.
  • 7Higenbottam T, Kuwano K, Nemery B, et al. Understanding the mechanism of drug-associated interstitial lung disease[J]. Br J Cancer, 2004, 91(supp12) .- S31-S37.
  • 8Camus P, Kudoh S, Ebina M. Interstitial lung disease associ- ated with drug therapy[J]: Br J Cancer, 2004, 91 (2) : S18- S23.
  • 9Liu X, Hong XN, Gu YJ, et al. Interstitial pneumonitis dur- ing rituximab containing chemotherapy for non-Hodgkin lym- phoma[J]. Leuk Lymphoma, 2008, 49(9): 1778-1783.
  • 10Ennishi D, Terui Y, Yokoyama M, et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab [J]. Int J Hematol, 2008, 87(4): 393-397.

引证文献3

二级引证文献8

临床肺科杂志
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部